KSCP
APFCP
SIUCP-ETS
NSCRD
Search
- Page Path
- HOME > Search
- Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients
- Bo-Young Oh, Ryung-Ah Lee, Soon-Sup Chung, Kwang Ho Kim
- J Korean Soc Coloproctol. 2011;27(3):127-132. Published online June 30, 2011
- DOI: https://doi.org/10.3393/jksc.2011.27.3.127
- 5,034 View
- 40 Download
- 15 Citations
-
Abstract
PDF Purpose The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and tumor progression of colorectal cancer and leads to the activation of intracellular signaling pathways. The use of anti-EGFR-targeted therapy has increased for patients with colorectal cancer, but patients with EGFR mutations will be resistant to anti-EGFR-targeted therapy. The identification of gene mutations is critical in cancer treatment; therefore, the aim of this study is to investigate the incidences of EGFR mutations in colorectal cancer patients in Korea.
Methods We retrospectively reviewed 58 colorectal cancer patients who underwent surgery between 2003 and 2006. We analyzed their EGFR mutations in four loci by DNA sequencing. In addition, we analyzed the correlation between the presence of EGFR mutation and patients' clinicopathologic features.
Results Of the 58 patients, 35 patients were male and 23 were female. Their mean age was 63.28 ± 11.18 years. Two patients (3.45%) were diagnosed as stage Tis, 7 patients (12.07%) as stage I, 24 patients (41.38%) as stage II, 20 patients (34.48%) as stage III, and 5 patients (8.62%) as stage IV. As a result of mutational analysis, EGFR mutations on exon 20 were detected in 13 patients (22.41%, G→A transitions). No EGFR mutations were detected on exons 18, 19, and 21. EGFR mutation was increased in the earlier stage and in the absence of lymph node metastasis (P = 0.028).
Conclusion The incidence of EGFR mutation in Korean colorectal cancer patients is 22.41%. In addition, EGFR mutation was significantly increased in the earlier stage and in the absence of lymph node metastasis.
-
Citations
Citations to this article as recorded by
- Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
Nagasundaram Nagarajan, Chittibabu Guda
Frontiers in Pharmacology.2024;[Epub] CrossRef - Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics
Claiborne W. Tydings, Bhuminder Singh, Adam W. Smith, Kaitlyn V. Ledwitch, Benjamin P. Brown, Christine M. Lovly, Allison S. Walker, Jens Meiler
Protein Science.2024;[Epub] CrossRef - Gut-associated lymphoid tissue carcinoma analyzed using next-generation sequencing: A case report
Naomi Sato, Sadahide Ono, Kurodo Kamiya, Noriyuki Uesugi, Fumiyoshi Fujishima, Hiroshi Kawachi, Tamotsu Sugai
Pathology - Research and Practice.2024; 263: 155621. CrossRef - Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges
Chiara Tramontano, Luca De Stefano, Ilaria Rea
Marine Drugs.2023; 21(5): 266. CrossRef - Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
Syeda Abida Ejaz, Mubashir Aziz, Mohamed Fawzy Ramadan, Ammara Fayyaz, Muhammad Sajjad Bilal
Molecules.2023; 28(10): 4044. CrossRef - Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings
Dylan Haynes, Eric E. Morgan, Emily Y. Chu
Human Pathology.2023; 140: 129. CrossRef - Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response
Tae Hoon Lee, Bum‐Sup Jang, Ji Hyun Chang, Eunji Kim, Jeong Hwan Park, Eui Kyu Chie
Cancer Medicine.2023; 12(14): 15664. CrossRef - Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives
Joao Manzi, Camilla O. Hoff, Raphaella Ferreira, Agustin Pimentel, Jashodeep Datta, Alan S. Livingstone, Rodrigo Vianna, Phillipe Abreu
Cancers.2023; 15(11): 3023. CrossRef - NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes
Ryan Timothy D. Yu, Reynaldo L. Garcia
Scientific Reports.2020;[Epub] CrossRef - Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling
Alberto Izzotti, Chiara Ceccaroli, Marta Geretto, Filippo Grillo Ruggieri, Sara Schenone, Emilio Di Maria
Cancers.2020; 12(6): 1652. CrossRef - Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
Marcel Wiesweg, Stefan Kasper, Karl Worm, Thomas Herold, Henning Reis, Linda Sara, Martin Metzenmacher, Annalena Abendroth, Kaid Darwiche, Clemens Aigner, Heiner H. Wedemeyer, Fabian A. Helfritz, Martin Stuschke, Brigitte Schumacher, Peter Markus, Andreas
Oncogene.2019; 38(16): 2953. CrossRef - Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer
Evangelos Koustas, Michalis V. Karamouzis, Chrysovalantou Mihailidou, Dimitrios Schizas, Athanasios G. Papavassiliou
Cancer Letters.2017; 396: 94. CrossRef - Lack of Mutations in Protein Tyrosine Kinase Domain Coding Exons 19 and 21 of the EGFR Gene in Oral Squamous Cell Carcinomas
Dhaval Tushar Mehta, Thangavelu Annamalai, Arvind Ramanathan
Asian Pacific Journal of Cancer Prevention.2014; 15(11): 4623. CrossRef - Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis
Shoude Zhang, Jia Chen, Hua Jiang, Haina Ma, Beibei Yang
European Journal of Clinical Pharmacology.2012; 68(5): 561. CrossRef - Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
Dong-Guk Park
Journal of the Korean Society of Coloproctology.2011; 27(3): 103. CrossRef
- Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
- Analysis of c-kit Gene Mutation and Prognostic Factors of GISTs in the Small and the Large Bowel.
- Park, Jong Kyung , Yun, Sang Seob , Kang, Won Kyung , Cho, Hyeon Min , Kim, Ji Youn , Choi, Seung Hye , Oh, Seong Taek , Oh, Se Jeong , Oh, Seong Lee , Jeon, Hae Myung
- J Korean Soc Coloproctol. 2004;20(1):1-7.
- 1,204 View
- 2 Download
-
Abstract
PDF
- PURPOSE
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors which arise anywhere in the tubular GI tract. The prognosis for GISTs that develop in the small and the large bowel is worse than it is for those that develop at other sites. We examined the significance of c-kit mutation as an independent prognostic factor for GISTs.
METHODS
The hospital records of 27 patients with GISTs in the small and the large bowel who were seen from January 1991 to December 2001 at the Department of Surgery, The Catholic University School of Medicine, were reviewed. c-kit mutation was measured by using the PCR and DNA sequencing.
RESULTS
Mutations in exon 11 were found in 5 cases (83.3%), exon 9 in 1 case (16.7%), and no mutations were noted in exon 13 and exon 17. All mutations in exon 11 were found in codon 560-570. c-kit mutation was observed more frequently in high-risk patients, and there was a significant difference between c-kit mutation and the survival rate (P=0.048).
CONCLUSIONS
We think that codon 550~560 in exon 11 of the c-kit gene is a hotspot of mutation, but c-kit mutation is uncertain as an independent prognostic factor for GISTs.
First
Prev- Page of 1
- Next
- Last
TOP
